Dongfeng Gu

Professor

Dongfeng Gu

  • Vice President
  • Southern University of Science and Technology
  • China
  • Year elected: 2023

Types of Fellowship

  • Life Fellow

Areas of expertise

  • Epidemiology of chronic diseases such as cardiovascular diseases, population prevention and treatment strategies, and genetic risk factors

BIO

Gu Dongfeng is academician of Chinese Academy of Sciences, former Deputy Director of National Center for Cardiovascular Diseases, former Vice President  of Fuwai Hospital Chinese Academy of Medical Sciences, Acting Vice President of Southern University of Science and Technology (SUSTech) and Chair Professor of Medical College of SUSTech. He obtained his bachelor’s degree of medicine in Nanjing Medical University in 1983, master degree of medicine and PhD degree in 1986 and 2007 respectively in Peking Union Medical College. He was a visiting scholar from 1990 to 1992, in Department of Epidemiology, University of Minnesota, USA, a visiting scholar in University of Toronto, Canada in 1997, and also as a visiting professor in Division of Human Genetics, University of Southampton, UK from Feb, 1999 to Feb, 2000.
 
He currently serves as the Vice President of Chinese Preventive Medicine Association, member of the expert consultation panel of Healthy China initiative, committee member of Medical Science Department of Academic Advisory Committee of Chinese Academy of Medical Sciences, and Deputy Director of Pharmaceutical Sciences, Health and Environment, Biomedical Engineering and Information Science Department of Academic Advisory Committee of Chinese Academy of Medical Sciences.
 
Dr. Gu is a professor with specialties in preventive cardiology, epidemiology, and medical genetics as well. During the past thirty years, Dr. Gu has made outstanding contributions in the area of preventive cardiology and genetic etiology for cardiovascular disease, including helping identify major causes of death and main risk factors for cardiovascular diseases in Chinese adults, developed risk prediction model of cardiovascular diseases in China, formulated guidelines for cardiovascular disease prevention and control, and led genomic risk assessment for hyperlipidemia and coronary heart disease.
 
He was awarded 16 national patents and two second prize award of National Science and Technology Progress Award. More than 300 SCI papers have been published, and his research results have been widely cited by domestic and international guidelines of disease prevention and control, authoritative textbooks and monographs of the World Health Organization.